Bristol-Myers Squibb Co. (BMY) PT Raised to $76 at Truist Securities, Revlimid Erosion Remains Key Investor Concern
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $76.00 (from $74.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
